Lenacapavir Drug Latest News
Recently, the United States Food and Drug Administration (FDA) approved Lenacapavir (LEN), the most promising HIV prevention medicine to be made so far.
About Lenacapavir Drug
- Lenacapavir is an antiretroviral medicine that is used for HIV prevention as a pre-exposure prophylaxis or PrEP.
- PrEP is a medication that can reduce the risk of HIV infection for individuals who are HIV-negative but are at risk of contracting the virus.
- The results of two key studies have shown that it helps prevent 99.9 per cent of all HIV transmission.
- LEN is an injectable PrEP that is to be taken twice yearly.
- It is developed by Gilead Sciences and marketed under the brand name Yeztugo.
How does lenacapavir work?
- Lenacapavir is a capsid inhibitor, a class of drugs that blocks the protein shell (capsid) the HIV virus needs to replicate.
- Unlike oral PrEP pills that must be taken daily, lenacapavir is administered as an injection once every six months, providing a discreet and highly effective method of prevention.
Source: IE
Lenacapavir Drug FAQs
Q1: Who invented lenacapavir?
Ans: Gilead Sciences
Q2: What is HIV/AIDS?
Ans: Acquired immunodeficiency syndrome (AIDS) is a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV).
